Drug Profile
TV 3606
Latest Information Update: 16 May 2005
Price :
$50
*
At a glance
- Originator Teva Pharmaceutical Industries
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 16 May 2005 Phase-I clinical trials in Multiple sclerosis in Europe (PO)